Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.

MLA

Vella, Serena, et al. “Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.” PloS One, vol. 11, no. 11, Nov. 2016, p. e0166233. EBSCOhost, https://doi.org/10.1371/journal.pone.0166233.

APA

Vella, S., Tavanti, E., Hattinger, C. M., Fanelli, M., Versteeg, R., Koster, J., Picci, P., & Serra, M. (2016). Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PloS One, 11(11), e0166233. https://doi.org/10.1371/journal.pone.0166233

Chicago

Vella, Serena, Elisa Tavanti, Claudia Maria Hattinger, Marilù Fanelli, Rogier Versteeg, Jan Koster, Piero Picci, and Massimo Serra. 2016. “Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.” PloS One 11 (11): e0166233. doi:10.1371/journal.pone.0166233.